Global clinical trial for drug to treat Kala Azar to take place in 2021
News:Pharma major Novartis and the Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for Kala …
Read More